Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | GPR3 | P46089 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29539238 | 0.89 | KMT2A (0.56) | KDM4EKMT2AALDH1A1GAAHPGD | |
| SCHEMBL1415347 | 0.87 | KMT2A (0.55) | KDM4EKMT2AALDH1A1GAAHPGD | |
| SCHEMBL29099832 | 0.85 | KMT2A (0.53) | KDM4EKMT2AALDH1A1GAAHPGD | |
| SCHEMBL29099831 | 0.84 | KDM4E (0.47) | KDM4EKMT2AALDH1A1GAAHPGD | |
| SCHEMBL12533981 | 0.83 | KMT2A (0.64) | KDM4EKMT2AALDH1A1GAAHPGD | |
| SCHEMBL29099859 | 0.83 | KDM4E (0.46) | KDM4EKMT2AALDH1A1GAAHPGD | |
| SCHEMBL29099825 | 0.83 | ADORA3 (0.42) | KDM4EKMT2AALDH1A1GAAHPGD | |
| SCHEMBL29099807 | 0.81 | KMT2A (0.45) | KDM4EKMT2AALDH1A1GAAHPGD | |
| SCHEMBL29099818 | 0.81 | USP2 (0.48) | KDM4EKMT2AALDH1A1GAAHPGD | |
| SCHEMBL7067981 | 0.81 | KDM4E (0.56) | KDM4EKMT2AALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116969889-B | Preparation method of phenanthridine or chiral phenanthridine compound | 瑞博(杭州)医药科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-116969889-A | Preparation method of phenanthridine or chiral phenanthridine compound | 瑞博(杭州)医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023182835-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME | 솔루스첨단소재 주식회사 | 2023-09-28 | — | — | WO | disclosed |
| EP-1831167-B1 | LIQUID PHASE PROCESS FOR THE SYNTHESIS OF ANNULATED PYRIDINES OVER ZEOLITE TYPE MOLECULAR SIEVE CATALYSTS | COUNCIL SCIENT IND RES (IN) | 2011-07-13 | — | — | EP | disclosed |
| US-7491828-B2 | Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2009-02-17 | — | — | US | disclosed |
| EP-1831167-A1 | LIQUID PHASE PROCESS FOR THE SYNTHESIS OF ANNULATED PYRIDINES OVER ZEOLITE TYPE MOLECULAR SIEVE CATALYSTS | Council of Scientific and Industrial Research (IN) | 2007-09-12 | — | — | EP | disclosed |
| US-20060149068-A1 | Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-06 | — | — | US | disclosed |
| WO-2006070403-A1 | LIQUID PHASE PROCESS FOR THE SYNTHESIS OF ANNULATED PYRIDINES OVER ZEOLITE TYPE MOLECULAR SIEVE CATALYSTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-06 | — | — | WO | disclosed |
| EP-0045171-B1 | 9-AMINO-1-HYDROXYOCTAHYDROBENZO(C)QUINOLINES AND DERIVATIVES THEREOF | PFIZER INC. (US) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149068-A1 | Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts | AURKA, CDK4, SKP2 | KDM4E 526/4885KMT2A 1064/4885ALDH1A1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.